<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39385128</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Post-viral symptoms and conditions are more frequent in COVID-19 than influenza, but not more persistent.</ArticleTitle><Pagination><StartPage>1126</StartPage><MedlinePgn>1126</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1126</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-10059-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Post-viral symptoms have long been known in the medical community but have received more public attention during the COVID-19 pandemic. Many post-viral symptoms were reported as particularly frequent after SARS-CoV-2 infection. However, there is still a lack of evidence regarding the specificity, frequency and persistence of these symptoms in comparison to other viral infectious diseases such as influenza.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We investigated a large population-based cohort based on German routine healthcare data. We matched 573,791 individuals with a PCR-test confirmed SARS-CoV-2 infection from the year 2020 to contemporary controls without SARS-CoV-2 infection and controls from the last influenza outbreak in 2018 and followed them up to 18 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that post-viral symptoms as defined for COVID-19 by the WHO as well as tissue damage were more frequent among the COVID-19 cohort than the influenza or contemporary control cohort. The persistence of post-viral symptoms was similar between COVID-19 and influenza.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Post-viral symptoms following SARS-CoV-2 infection constitute a substantial disease burden as they are frequent and often persist for many months. As COVID-19 is becoming endemic, the disease must not be trivialized. Research should focus on the development of effective treatments for post-viral symptoms.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tesch</LastName><ForeName>Falko</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany. Falko.tesch@ukdd.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehm</LastName><ForeName>Franz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loser</LastName><ForeName>Friedrich</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Techniker Krankenkasse, Bramfelder Straße 140, Hamburg, 22305, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bechmann</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IKK classic, Tannenstraße 4b, Dresden, 01099, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vivirito</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>InGef - Institute for Applied Health Research Berlin GmbH, Otto-Ostrowski-Straße 5, Berlin, 10249, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wende</LastName><ForeName>Danny</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>BARMER Institut Für Gesundheitssystemforschung (bifg), Axel-Springer-Straße 44, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batram</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vandage GmbH, Detmolder Str. 30, Bielefeld, 33604, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buschmann</LastName><ForeName>Tilo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>AOK PLUS, Sternplatz 7, Dresden, 01067, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menzer</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IKK classic, Tannenstraße 4b, Dresden, 01099, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludwig</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>InGef - Institute for Applied Health Research Berlin GmbH, Otto-Ostrowski-Straße 5, Berlin, 10249, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roessler</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BARMER Institut Für Gesundheitssystemforschung (bifg), Axel-Springer-Straße 44, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seifert</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margolis</LastName><ForeName>Giselle Sarganas</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Robert Koch Institute, Nordufer 20, Berlin, 13353, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitzle</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Robert Koch Institute, Nordufer 20, Berlin, 13353, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>König</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Techniker Krankenkasse, Bramfelder Straße 140, Hamburg, 22305, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulte</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>BARMER Institut Für Gesundheitssystemforschung (bifg), Axel-Springer-Straße 44, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hertle</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>BARMER Institut Für Gesundheitssystemforschung (bifg), Axel-Springer-Straße 44, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballesteros</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>BARMER Institut Für Gesundheitssystemforschung (bifg), Axel-Springer-Straße 44, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baßler</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AOK PLUS, Sternplatz 7, Dresden, 01067, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertele</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Techniker Krankenkasse, Bramfelder Straße 140, Hamburg, 22305, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bitterer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>IKK classic, Tannenstraße 4b, Dresden, 01099, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riederer</LastName><ForeName>Cordula</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>DAK-Gesundheit, Großer Burstah 23, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobik</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>DAK-Gesundheit, Großer Burstah 23, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheidt-Nave</LastName><ForeName>Christa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Robert Koch Institute, Nordufer 20, Berlin, 13353, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Claims data</Keyword><Keyword MajorTopicYN="N">Cohort study</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Post-COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>FT, FE, AV, ML, MS, GM, LR, CS, and JS and report institutional funding for this project from the German Federal Ministry of Health. Unrelated to this study, JS reports institutional grants for investigator-initiated research from the German Federal Joint Committee, German Ministry of Health, German Ministry of Research, European Union, German Federal State of Saxony, Novartis, Sanofi, ALK, and Pfizer. He participated in advisory board meetings as a paid consultant for Sanofi, Lilly, and ALK. JS serves the German Ministry of Health as a member of the German National Council for Health and Care. MB reports payment for data analysis which is presented in this paper from DAK-Gesundheit. Unrelated to this study, MB reports grants from German GBA, Pfizer, and Sanofi Pasteur and consulting fees from Janssen-Cilag. He participated in an advisory board for GSK. The other authors declare that they have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>23</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39385128</ArticleId><ArticleId IdType="pmc">PMC11465902</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-10059-y</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-10059-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28:911–23.</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, Baizer L, Goldman JD, Rouphael N, Deitchman A, et al. Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. Front Immunol. 2023;14:1129459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10034329</ArticleId><ArticleId IdType="pubmed">36969241</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, Ekka-Zohar A, Ben David SS, Lerner U, Bivas-Benita M, Greenfeld S. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380:e072529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023;29:2347–57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, Lowe DJ, McAuley A, Mills NL, Winter AJ, Black C, Scott JT, O’Donnell CA, Blane DN, Browne S, et al. Natural history of long-COVID in a nationwide, population cohort study. Nat Commun. 2023;14:3504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10263377</ArticleId><ArticleId IdType="pubmed">37311808</ArticleId></ArticleIdList></Reference><Reference><Citation>Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, Wende D, Vivirito A, Toepfner N, Ehm F, et al. Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany. PLoS Med. 2022;19:e1004122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9648706</ArticleId><ArticleId IdType="pubmed">36355754</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H, Kuo CF, Yu TS, Ke LY, Hung CL, Tsai SY. Increased risk of chronic fatigue syndrome following infection: a 17-year population-based cohort study. J Transl Med. 2023;21:804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10638797</ArticleId><ArticleId IdType="pubmed">37951920</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9:129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. WHO clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Buda S, Preuß B,Biere B, Wedde M, Dürrwald R. Vorläufige Ergebnisse zur Wirksamkeit der saisonalen Influenzaimpfung bei ambulant behandelten Patienten in der Saison 2017/18 in Deutschland. Epid Bull. 2018;6:69–70.</Citation></Reference><Reference><Citation>Rondy M, Kissling E, Emborg H-D, Gherasim A, Pebody R, Trebbien R, Pozo F, Larrauri A, McMenamin J, Valenciano M. group I-MI-M: Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. Eurosurveillance. 2018;23:18–00086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5840921</ArticleId><ArticleId IdType="pubmed">29510782</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">35378455</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung KW, Baye F, Baik SH, Zheng Z, McDonald CJ. Prevalence and characteristics of long COVID in elderly patients: An observational cohort study of over 2 million adults in the US. PLoS Med. 2023;20:e1004194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10150975</ArticleId><ArticleId IdType="pubmed">37068113</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, Nicholson T, Akrami A, Apfelbacher C, Chen J, De Groote W, Diaz JV, Gorst SL, Harman N, Kokorina A, et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022;10:715–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197249</ArticleId><ArticleId IdType="pubmed">35714658</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21:383–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilbe JM. Negative binomial regression. 2nd ed. Cambridge: Cambridge University Press; 2011.</Citation></Reference><Reference><Citation>Cameron AC, Trivedi PK. Regression Analysis of Count Data Book. 2nd ed. Cambridge: Cambridge University Press; 2013.</Citation></Reference><Reference><Citation>Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53:457–81.</Citation></Reference><Reference><Citation>R Core Development Team: R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.</Citation></Reference><Reference><Citation>Reme BA, Gjesvik J, Magnusson K. Predictors of the post-COVID condition following mild SARS-CoV-2 infection. Nat Commun. 2023;14:5839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10511472</ArticleId><ArticleId IdType="pubmed">37730740</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Strobl R, Apfelbacher C, Bahmer T, Geisler R, Heuschmann P, Horn A, Hoven H, Keil T, Krawczak M, et al. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS-CoV-2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort. Infection. 2023;51(6):1–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10212223</ArticleId><ArticleId IdType="pubmed">37231313</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, Ward H, Elliott P. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 1957;2022:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonanad C, García-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-González V, Fácila L, Ariza A, Núñez J, Cordero A. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. J Am Med Dir Assoc. 2020;21:915–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247470</ArticleId><ArticleId IdType="pubmed">32674819</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, Huggins CF, Kwong ASF, Silverwood RJ, Di Gessa G, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13:3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-de-las-Peñas C, Torres-Macho J, Catahay JA, Macasaet R, Velasco JV, Macapagal S, Caldararo M, Henry BM, Lippi G, Franco-Moreno A, Notarte KI. Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review. Infection. 2024;52(1):43–58.</Citation><ArticleIdList><ArticleId IdType="pubmed">38113020</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao D, He X, Liu J, Xu L. Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period. Signal Transduct Target Ther. 2023;8:466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10739883</ArticleId><ArticleId IdType="pubmed">38129394</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan JQ, Tian ZM, Xue LB. Hyperbaric Oxygen Treatment for Long COVID: From Molecular Mechanism to Clinical Practice. Curr Med Sci. 2023;43:1061–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">37924387</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T, Menges D, Anagnostopoulos A, Domenghino A, Aschmann HE, Frei A, Fehr JS, Puhan MA. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. BMJ. 2023;381:e074425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, Liu M, Wang Y, Cui D, Wang Y, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10:863–76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study. Lancet Infect Dis. 2024;24(3):239–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">38104583</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn KL, Stukel TA, Huang A, Abdel-Qadir H, Altaf A, Bell CM, Cheung AM, Detsky AS, Goulding S, Herridge M, et al. Comparison of Medical and Mental Health Sequelae Following Hospitalization for COVID-19, Influenza, and Sepsis. JAMA Intern Med. 2023;183:806–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10282961</ArticleId><ArticleId IdType="pubmed">37338892</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan BKJ, Han R, Zhao JJ, Tan NKW, Quah ESH, Tan CJW, Chan YH, Teo NWY, Charn TC, See A, et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ. 2022;378:e069503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9326326</ArticleId><ArticleId IdType="pubmed">35896188</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis I, Fonseca-Rodríguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, Lindmark K, Fors Connolly AM. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377:e069590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8984137</ArticleId><ArticleId IdType="pubmed">35387772</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairweather D, Beetler DJ, Di Florio DN, Musigk N, Heidecker B, Cooper LT Jr. COVID-19, Myocarditis and Pericarditis. Circ Res. 2023;132:1302–19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10171304</ArticleId><ArticleId IdType="pubmed">37167363</ArticleId></ArticleIdList></Reference><Reference><Citation>Gornyk D, Harries M, Glöckner S, Strengert M, Kerrinnes T, Heise J-K, Maaß H, Ortmann J, Kessel B, Kemmling Y, et al. SARS-CoV-2 Seroprevalence in Germany. Dtsch Arztebl International. 2021;118:824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8888869</ArticleId><ArticleId IdType="pubmed">35191825</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>